Objectives: Much progress has been made in understanding the main causes of blood culture-negative endocarditis (BCNE). Few studies concerning BCNE treatment (due to previous antibiotics used or fastidious pathogens) are available. We performed this study to evaluate the effectiveness of our therapeutic protocol in BCNE, based on compliance with the protocol, outcome and 1 year mortality.
Introduction
Blood culture-negative endocarditis (BCNE) refers to definite or probable endocarditis in which no causative microorganism can be grown in three or more aerobic and anaerobic blood cultures, using the usual laboratory methods. The incidence of BCNE among all cases of endocarditis varies from 2.5% to 48%, depending on the series. 1 -3 Various factors contribute to this variation in incidence, such as early use of antibiotics prior to the diagnosis of infective endocarditis (IE), the role of fastidious microorganisms or zoonotic microorganisms and different diagnostic procedures performed. Diagnosis of BCNE constitutes a challenge, since the delay between diagnosis and appropriate treatment determines the clinical outcome of the patient. In our centre, we use a systematic sampling strategy to investigate BCNE, which includes serological testing for Coxiella burnetii, Bartonella sp. and other fastidious agents (Legionella pneumophila and Mycoplasma pneumoniae), nuclear antibodies and rheumatoid factor 4 as first-line tests. Second-line tests include molecular detection targeting specifically staphylococci, streptococci, enterococci, Tropheryma whipplei and Bartonella sp. performed on blood specimens. In addition, specific PCR, 16S and 18S RNA PCR 3 and histopathological techniques 5 are performed on valvular biopsy, if available. 6 This comprehensive diagnostic strategy is not available in many centres. The selection of the most appropriate medical therapy in this situation is difficult and is initially empirical. European guidelines 7 recommend empirical BCNE treatment with amoxicillin/clavulanic acid combined with gentamicin in a community setting or vancomycin, gentamicin and rifampicin in patients with a prosthetic valve implanted during the previous year. These recommendations are based on the most common pathogens responsible for culture-positive endocarditis (staphylococci, Gram-negative bacilli, streptococci and enterococci), which are also often found in valvular specimens. 3 Moreover, fungi were identified as the most frequent pathogen in BCNE in early prosthetic valve endocarditis, justifying the need to add antifungal treatment to this empirical protocol in context-specific situations. 8 Much progress has been made in understanding the main causes of BCNE, demonstrating that uncommon or rare endocarditis pathogens such as C. burnetii and Bartonella sp. are major agents responsible for BCNE in France and other countries.
3, 9 The antibiotic treatments of choice have been described 10 -12 and a consultation with an infectious disease specialist is recommended to decide the most appropriate antibiotic protocol. 7 An antimicrobial stewardship programme is associated with greater adherence to recommended antimicrobial therapy practices in the management of infectious diseases. 13 In contrast, few articles concerning the treatment of BCNE sterilized by previous antibacterial treatment or caused by fastidious pathogens are available. To improve the prognosis of IE, we have implemented our therapeutic protocol since 2002, based on a local consensus and multidisciplinary management of IE with the involvement of a cardiologist, microbiologist, infectious disease specialist and surgical specialist. Taking advantage of our large database, we have already evaluated the impact of our strategy in IE and have shown a significant impact on IE management and outcome.
14 In this study, we aimed to evaluate the effectiveness of our therapeutic protocol in BCNE since 2002, based on compliance with the protocol, outcome and mortality at 1 year.
Patients and methods

Patients
We collected prospectively and analysed retrospectively cases of BCNE seen at La Timone Hospital, Marseille, between 2002 and 2014. For each studied patient, demographic data (age and sex), clinical data [valvular prosthesis, intravenous drug abuse (IVDA), intracardiac device, renal insufficiency and cancer], microbiological, transthoracic and transoesophageal echocardiography data, positron emission tomography (PET) and CT data when available, diagnostic criteria, treatment and outcome were collected in our database.
Diagnostic procedures
During the study period, all patients with IE (blood culture-positive and -negative IE) were prospectively classified by the multidisciplinary endocarditis group using the modified Duke criteria. 15 All microbiological investigations were performed with a 'diagnostic kit' for endocarditis, 16 including three sets of blood cultures and detection of specific antibodies directed against C. burnetii, Bartonella sp., Brucella sp., Aspergillus sp., L. pneumophila, M. pneumoniae, Chlamydia pneumoniae and detection of rheumatoid factor, anticardiolipin 17 and serum concentration of specific IgE to pig epithelium. 18 BCNE was defined as a patient with IE in whom we were unable to isolate any pathogen in standard blood cultures. We systematically performed cultures, molecular detection methods 6 and histopathological analysis on the surgically excised valves as previously described. 5 When results of first-rank tests were negative, we systematically performed molecular detection of C. burnetii, Bartonella sp., T. whipplei, Mycoplasma sp., Streptococcus mitis, Streptococcus gallolyticus, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus from EDTA blood 3 and Bartonella sp. western blot. 19 
Final diagnosis
During the first 15 days after admission, we established the final diagnosis of IE according to the modified Duke criteria: we took into account molecular evidence of bacterial infection as a major criterion and our 'diagnostic kit' results. When the results of all assays were negative, we met with the physicians in charge of the patient to enquire about any neoplastic or autoimmune disease that would have been diagnosed elsewhere, in order to rule out IE. In our study, we did not consider C. burnetii and Bartonella sp. IE as well as neoplastic or autoimmune endocarditis.
Antimicrobial protocol
Since 2002, we have used a simplified and standardized protocol developed by our multidisciplinary team. 14, 20 The antimicrobial protocol in IE of unknown aetiology includes only four intravenous antimicrobial agents: amoxicillin, vancomycin, gentamicin and amphotericin B. We apply two types of protocol to treat BCNE. The first one concerns community-acquired BCNE and consists of 6 weeks of amoxicillin (12 g/day) and 3 weeks of gentamicin (3 mg/kg/day). The second protocol concerns hospital-acquired BCNE (nosocomial IE), including healthcare-associated IE (with implantable venous access device or dialysis patients) and post-surgical IE (,12 months) (valvular surgery or intracardiac devices implantation). It consists of 6 weeks of vancomycin (30 mg/kg/day) and 3 weeks of gentamicin (3 mg/kg/day). Since 2004, for patients with recent cardiovascular surgery (hospital-acquired BCNE), liposomal amphotericin B (3 mg/kg/ day) was added if the fever persisted after 48 h, in association with the previous empirical antibiotic treatment. 8 Gentamicin, vancomycin and amphotericin B trough levels were performed within 48 h of starting treatment and then twice weekly. Renal function was followed by daily urea and creatinine assay. See Figure 1 .
Outcome
All events occurring within 1 year after the first day of hospitalization were obtained by systematic consultations (1, 3 and 6 months and 1 year after the medical treatment of IE). In cases of patients without follow-up (those who had no consultation) their physician was contacted retrospectively. We recorded death from all causes and IE recurrences were defined as a new episode of possible or definite IE.
Evaluation of the protocol
Compliance with the protocol was evaluated as follows: (i) administration of antimicrobial agents according to the protocol (yes/no); and (ii) duration of treatment according to the protocol (yes/no).
The causes of death were investigated and classified in different categories (heart failure, multiple organ failure syndrome, embolic complications and other, unknown causes). Mortality at 1 year after baseline (day of definite diagnosis) caused by an infectious episode was recorded.
Mortality from BCNE was compared with blood culture-positive IE for the most frequently isolated pathogens (S. aureus, Streptococcus a-haemolytic, S. gallolyticus, CoNS, Enterococcus sp. and fungi) included in our database from 2002 to 2014.
Statistical analysis
Categorical variables were expressed as numbers and percentages and were compared by using the two-tailed Fisher's exact test. Continuous variables were described using the median and IQR and compared using the Mann -Whitney test. For all tests, statistical significance was determined when P, 0.05. All statistical analyses were performed using Statview 5.0.
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Literature review
To compare the mortality rate in BCNE in Marseille using our protocol with those reported in the literature, we conducted a literature search using MEDLINE, without time limits, cross-referencing the following search terms: BCNE treatment, IE treatment, mortality rate, in-hospital mortality and outcome infective endocarditis. Only articles written in English and French and dealing with human cases were reviewed.
Results
Characteristics of the study population
From 2002 to 2014, we retrospectively selected 177 patients with definite IE admitted to the cardiology or cardiac surgery departments in La Timone Hospital, Marseille and treated for BCNE in our centre. Among these patients, 124 (70.1%) were classified as community-acquired IE and 53 (29.9%) as nosocomial IE. Before starting treatment, 3 (1.7%) patients of the study population had renal failure. All patients received the 'endocarditis kit'. The mean age was 66 years and 116 (65.5%) patients were male. Concerning cardiac predisposing conditions, 55 (31.1%) patients had native valves, 59 (33.3%) had prosthetic valves, 49 (27.7%) had intracardiac devices and 14 (7.9%) had both prosthetic valves and medical devices. In addition to medical treatment, 55 (31.1%) patients underwent valvular surgery, 48 (27.1%) had percutaneous extraction of intracardiac devices and 2 (1.1%) underwent both procedures. Only one (0.6%) patient had surgical extraction of an implantable venous access device. 
Characteristics of the BCNE group
The community-acquired BCNE group were divided into two different groups: 83 (46.9%) patients with left-sided IE and 41 (23.2%) patients with right-sided IE. Concerning left-sided IE, the sites of infection were native valves in 43 (51.8%) cases, bioprosthetic valves in 31 (37.3%) cases, mechanical valves in 8 (9.6%) cases and valvuloplasty in 1 (1.2%) case. Concerning right-sided IE, the sites of infection were intracardiac devices in 36 (87.8%) cases, IE on a tricuspid valve in 1 (2.4%) case and IE in IVDA in 4 (9.7%) cases. The fatality rate was 5.6% (7/124) and left-sided IE was not associated with significantly more deaths than rightsided IE (P ¼ 0.56).
The nosocomial BCNE group was divided into two groups: postsurgical IE (,12 months) including 44 (24.9%) patients with postvalvular surgery IE for 24 (54.5%) cases and intracardiac devices for 20 (45.5%) cases; and other nosocomial IE including 9 patients (5%) such as BCNE due to dialysis or an implantable venous device. The fatality rate was 3.8% (2/53) and other nosocomial BCNE was not associated with significantly more deaths than post-surgical IE (P ¼ 0.28). For the nosocomial BCNE group, the sites of infection were bioprosthetic valves (,12 months) in 22 (41.5%) patients, mechanical valves (,12 months) in 2 (3.8%) patients, intracardiac devices in 20 (37.7%) patients, dialysis catheter in 3 (5.7%) patients and other nosocomial sites in 6 (11.3%) patients. The community-acquired BCNE fatality rate (5.6%) was not significantly higher than the nosocomial BCNE fatality rate (P¼0.73).
Application of our antibiotic protocol
Regarding the community-acquired BCNE group, our protocol was applied and justified in 113 (91.1%) cases (Table 1 ). In 11 (8.8%) cases, the protocol was not applied (Table 2 ); 7 patients belonged to the left-sided IE group and all of them were treated with vancomycin and gentamicin. The reasons for this non-compliance were penicillin allergy in three cases, Verneuil's disease (with multiple surgeries) in two cases, one case of relapse and one patient who had vascular surgery within 1 year. The other four cases belong to the right-sided IE group. One received vancomycin alone; he had received treatment with aminoglycosides a few days previously for pneumonia in the ICU. The second patient received sulfamethoxazole/trimethoprim and clindamycin in 
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Blood culture endocarditis empirical treatment JAC combination, related to his pacemaker culture with Staphylococcus schleiferi. The third one received imipenem and gentamicin according to the pacemaker culture demonstrating Pseudomonas stutzeri and Corynebacterium minutissimum. The final patient received colistin, vancomycin and fluconazole due to multiple sites of infection in addition to IE. Regarding the nosocomial BCNE group, the protocol was not applied in only two (3.7%) patients. Both of them had renal failure and were treated with vancomycin. They had post-surgical IE (,12 months).
The duration of treatment was not respected in 10 (5.6%) cases (Table 3) . Allergy was noted in three cases and an amoxicillin side effect (neutropenia) in one case, which required changing antibiotics. Concerning four cases of left-sided IE, we switched amoxicillin and gentamicin for vancomycin and gentamicin because of a poor clinical course in two of them and persistence of ultrasound images in the other two cases. In one case of right-sided IE, we switched vancomycin and gentamicin after 3 days in favour of our co-trimoxazole and clindamycin protocol because of a positive intracardiac device culture for S. aureus.
21
In one case of post-valvular surgery IE, we had to switch vancomycin and gentamicin for co-trimoxazole and clindamycin because of discharge against medical advice.
Results of cultures and molecular detection methods on surgically excised valves or intracardiac devices
As previously explained, we systematically performed cultures, molecular detection methods and histopathological analyses on the surgically excised valves or intracardiac devices when available. This allowed identification of the pathogens responsible for BCNE and thus an evaluation of the protocol. In our study, surgery was performed in 106 (59.9%) cases. The types of treatment were valvular surgery in 55 (51%) cases, extraction of intracardiac The majority of the pathogens identified from these surgical samples (Table 4) were Staphylococcus epidermidis in 14 (13.2%) cases, followed by Propionibacterium acnes in 10 (9.4%) cases. Other pathogens frequently responsible for IE were found, such as S. aureus (two cases), S. gallolyticus (two cases), Staphylococcus capitis (two cases), Streptococcus agalactiae, Enterococcus faecalis, Staphylococcus oralis, S. schleiferi, P. stutzeri, Corynebacterium striatum, Corynebacterium jeikeium, C. minutissimum and Paracoccus yeei (one case each).
Efficacy of our protocol
We classified the causes of death according to the type of IE and recorded mortality at 1 year after baseline (day of definite diagnosis). Overall, non-compliance with our protocol was not associated with significantly more deaths (P ¼ 0.63). Using our protocol, the fatality rate (Table 5 ) was 5.1%. Indeed, only 9 of the 177 patients died and 4 of them underwent cardiac surgery. Among the community-acquired BCNE group, the fatality rate was 5.6% (7/124). Five patients had left-sided IE and the causes of death were: embolic complication 10 days after baseline; post-surgical multiple organ failure syndrome 1 month after baseline; multiple organ failure syndrome 5 months after baseline; heart failure 1 month after baseline; and one unknown cause 7 months after baseline (Table 6) . Two patients had right-sided IE and the causes of death were: heart failure 1 month after baseline, 20 days after cardiac surgery; and multiple organ failure syndrome with postcardiac surgery sepsis in a patient with liver cirrhosis 5 months after baseline. Community-acquired BCNE treated with our protocol was not associated with a significantly lower fatality rate than community-acquired BCNE treated with another protocol (P ¼0.51).
Among the nosocomial BCNE group, the fatality rate was 3.8% (2/53). One patient had nosocomial IE; he was on renal dialysis but the cause of death was undetermined 6 days after baseline. The other patient with post-surgical IE (,12 months) died of heart failure 10 months after baseline, 3 days after emergency cardiac surgery. Nosocomial BCNE treated with our protocol was not associated with a significantly lower fatality rate than nosocomial BCNE treated with another protocol (P ¼ 0.92). We also recorded blood culture-positive endocarditis in-hospital mortality between 2002 and 2014 in our hospital (Table 7) . Compared with S. aureus endocarditis, S. gallolyticus endocarditis, Enterococcus sp. endocarditis and other blood culture-positive endocarditis, we founded that BCNE had significant lower in-hospital mortality.
Discussion
We performed this study to evaluate our empirical treatment of BCNE in 177 cases, between 2002 and 2014. The number of patients treated with both appropriate antimicrobial agents and appropriate duration of treatment was 154 (87.0%). The rate of compliance with our guidelines was similar to previous results reported in 2006 (82.3%). 14 We analysed the causes of inappropriate treatment in 13 (7.3%) cases and inappropriate duration in 10 (5.6%) cases. The changes of treatment were justified in all cases except one for discharge against medical advice. The fatality rate was 5.1% and all deaths occurred in our empirical treatment. Among the nine deaths, four were not attributable to empirical treatment failure because they occurred .1 month after stopping treatment. Concerning the other deaths, in three cases, the lack of surgical management in association with empirical treatment could explain the failure. Finally, two cases of heart failure 10 days and 1 day after cardiac surgery, respectively, could indicate poor tolerance of surgery.
In our cohort, the prevalence of BCNE with a final microbial diagnosis was 22.0%. In most of the cases, Gram-positive cocci such as staphylococci, streptococci and enterococci were found. The two reasons for negative blood culture were a fastidious microorganism (P. acnes, P. yeei, etc.) and the administration of antibiotics prior to blood culture. Detecting the causative 
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3 of 759 patients with BCNE, using blood PCR for the diagnosis of BCNE, the main bacterial agents identified were S. gallolyticus, S. mitis, Enterococcus sp., S. aureus, Escherichia coli and fastidious bacteria, in which the respective prevalence varied according to patient characteristics. Our results are similar to those obtained in other series, 22 -24 where staphylococci and streptococci can explain 30% -60% of the cases of BCNE when antibiotic treatment precedes blood culture. 25 Although previous antibiotic therapy is the most significant cause of BCNE, 22,26 -29 a substantial number of cases resulted from infection with obligate intracellular bacteria, 3 but in our cohort we excluded these aetiologies because they require specific treatment. Furthermore, without isolation of the microorganism, the antibiotic susceptibility of the infecting organism cannot be determined, making it difficult to decide on an initial choice of antibiotics. We found several studies where culture-positive and culture-negative IE were compared. Zamorano et al. 30 reported that patients with BCNE had a higher complication rate; in contrast, Garg et al., 25 from India, a country with a high prevalence of negative blood cultures secondary to previous antibiotic use, reported that cardiac surgery and total in-hospital mortality in BCNE were lower, but did not reach statistical significance. In the studies by Lamas et al., 27 Hoen et al.
24
and Ferrera et al., 31 no difference in the mortality rate was observed between BCNE and blood culture-positive IE. On the other hand, Botelho-Nevers et al., 14 in a multivariate analysis with a management-based approach to IE, reported an HR of IE of unknown etiology lower than S. aureus enterococci IE. The HR of IE of unknown aetiology was lower than those above.
Concerning the antibiotic treatment of BCNE, no evaluations have been made. The initial choice of empirical treatment, which aims to cover the most common pathogens, should cover staphylococci, streptococci and enterococci in community IE and, in case of healthcare-associated IE, should cover methicillinresistant staphylococci and enterococci. There are some published recommendations for empirical antibiotic treatment of BCNE, such as the European guidelines. 7 Ampicillin/flucloxacillin and cloxacillin or oxacillin are always the first drugs of choice in combination with an aminoglycoside if the site of infection is a native valve or a prosthetic valve .1 year old. In case of allergy, vancomycin and gentamicin are the most appropriate drugs and concerning prosthetic valves ,1 year old or drug-addicted patients, vancomycin combined with gentamicin and rifampicin are the recommended empirical treatments. Our protocol is close to these guidelines: we use amoxicillin instead of ampicillin and gentamicin in community-acquired IE and vancomycin combined with gentamicin allows us to cover most of the common pathogens in healthcare-associated IE. But following a previous study of BCNE in early prosthetic valve IE, which revealed a high prevalence of fungi, 8 in case of nosocomial post-surgical BCNE (, 12 months), we added an antifungal treatment (amphotericin B) to cover yeast if the fever persisted 48 h after antibiotic empirical treatment. In the literature, there is no evidence of a better empirical antibiotic therapy. In a 10 year survey of BCNE, Werner et al. 32 observed that aminoglycoside therapy was important for survival in BCNE. 33 Our mortality rate in this study (5.1%) is one of the lowest, compared with other studies (Table 8) , and we have the largest series of patients (177). It may result from a strategy that uses We noted only mortality at 1 year after baseline (day of definite diagnosis), caused by infectious episodes.
a sampling procedure and a standardized protocol at the same time. This strategy was possible as we are a specialized centre. The low mortality rate observed in our study may also be related to a more aggressive surgical approach. 34 In fact, 59.9% of all patients underwent surgery (valve surgery or intracardiac device extraction). Moreover, 31.6% of BCNE was observed on an intravascular device, which has been associated with a low mortality rate (10%) when complete removal of the device is performed 35 and up to 20% without removal of infected leads. 36 This study shows that our protocol is simple, safe and efficient. It is a viable choice for BCNE treatment. Our low BCNE mortality rate demonstrates the value of this protocol. Blood culture endocarditis empirical treatment JAC
